Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis

References

• Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–13. doi:10.1126/science.aaa8172.
   PubMed Web of Science ®Google Scholar
• Homet Moreno B, Ribas A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112(9):1421–27. doi:10.1038/bjc.2015.124.
   PubMed Web of Science ®Google Scholar
• Dine J, Gordon R, Shames Y, Kasler MK, Barton-Burke M. Immune checkpoint inhibitors: an innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs. 2017;4(2):127–35. doi:10.4103/apjon.apjon_4_17.
   PubMed Web of Science ®Google Scholar
• Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175(2):313–26. doi:10.1016/j.cell.2018.09.035.
   PubMed Web of Science ®Google Scholar
• Münz C, Lünemann JD, Getts MT, Miller SD. Antiviral immune responses: triggers of or triggered by autoimmunity. Nat Rev Immunol. 2009;9(4):246–58. doi:10.1038/nri2527.
   PubMed Web of Science ®Google Scholar
• Vojdani A. A potential link between environmental triggers and autoimmunity. Autoimmune Dis. 2014;2014:437231. doi:10.1155/2014/437231.
   PubMedGoogle Scholar
• Rose NR. Prediction and prevention of autoimmune disease in the 21st century: a review and preview. Am J Epidemiol. 2016;183(5):403–06. doi:10.1093/aje/kwv292.
   PubMed Web of Science ®Google Scholar
• Milchert M, Makowska J, Brzezińska O, Brzosko M, Więsik-Szewczyk E. Monogenic autoinflammatory diseases in adults - a challenge to rheumatologic practice at the onset of the Polish national programme of interleukin 1 inhibitor treatment. Reumatologia. 2019;57(6):326–35. doi:10.5114/reum.2019.91298.
   PubMedGoogle Scholar
• Simon D, Tascilar K, Fagni F, Krönke G, Kleyer A, Meder C, Atreya R, Leppkes M, Kremer AE, Ramming A, et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease. Ann Rheum Dis. 2021;80(10):1312–16. doi:10.1136/annrheumdis-2021-220461.
   PubMed Web of Science ®Google Scholar
• Dörner T, Jacobi AM, Lee J, Lipsky PE. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods. 2011;363(2):187–97. doi:10.1016/j.jim.2010.06.009.
   PubMed Web of Science ®Google Scholar
• Yang Y, Santamaria P. Evolution of nanomedicines for the treatment of autoimmune disease: from vehicles for drug delivery to inducers of bystander immunoregulation. Adv Drug Deliv Rev. 2021;176:113898. doi:10.1016/j.addr.2021.113898.
   PubMed Web of Science ®Google Scholar
• Sudres M, Verdier J, Truffault F, Le Panse R, Berrih-Aknin S. Pathophysiological mechanisms of autoimmunity. Ann N Y Acad Sci. 2018;1413(1):59–68. doi:10.1111/nyas.13560.
   PubMed Web of Science ®Google Scholar
• Kennedy LC, Bhatia S, Thompson JA, Grivas P. Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors. J Natl Compr Cancer Netw. 2019;17(6):750–57. doi:10.6004/jnccn.2019.7310.
   PubMed Web of Science ®Google Scholar
• Lee DJ, Lee HJ, Jr, Farmer JR, Reynolds KL. Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Cardiol Rep. 2021;23(8):98. doi:10.1007/s11886-021-01530-2.
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–29. doi:10.1056/NEJMoa1809064.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–39. doi:10.1016/S0140-6736(19)32222-6.
   PubMed Web of Science ®Google Scholar
• Franks AL, Slansky JE. Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res. 2012;32:1119–36.
   PubMed Web of Science ®Google Scholar
• Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer. 2011;10:33. doi:10.1186/1476-4598-10-33.
   PubMed Web of Science ®Google Scholar
• Xie W, Huang H, Xiao S, Fan Y, Deng X, Zhang Z. Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: a meta-analysis of observational studies. Autoimmun Rev. 2020;19(12):102687. doi:10.1016/j.autrev.2020.102687.
   PubMed Web of Science ®Google Scholar
• Shibaki R, Murakami S, Matsumoto Y, Goto Y, Kanda S, Horinouchi H, Fujiwara Y, Yamamoto N, Motoi N, Kusumoto M, et al. Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. Med Oncol. 2019;36(6):49. doi:10.1007/s12032-019-1274-0.
   PubMed Web of Science ®Google Scholar
• Tasaka Y, Honda T, Nishiyama N, Tsutsui T, Saito H, Watabe H, Shimaya K, Mochizuki A, Tsuyuki S, Kawahara T, et al. Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. Lung Cancer. 2021;155:120–26. doi:10.1016/j.lungcan.2021.03.014.
   PubMed Web of Science ®Google Scholar
• Cortellini A, Buti S, Santini D, Perrone F, Giusti R, Tiseo M, Bersanelli M, Michiara M, Grassadonia A, Brocco D, et al. Clinical outcomes of patients with advanced cancer and pre-existing autoimmune diseases treated with anti-programmed death-1 immunotherapy: a real-world transverse study. Oncologist. 2019;24(6):e327–37. doi:10.1634/theoncologist.2018-0618.
   PubMed Web of Science ®Google Scholar
• Loriot Y, Sternberg CN, Castellano D, Oosting SF, Dumez H, Huddart R, Vianna K, Alonso Gordoa T, Skoneczna I, Fay AP, et al. Safety and efficacy of atezolizumab in patients with autoimmune disease: subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma. Eur J Cancer. 2020;138:202–11. doi:10.1016/j.ejca.2020.07.023.
   PubMed Web of Science ®Google Scholar
• Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, Yoshida H, Akai M, Mio T, Hirai T. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer. 2018;9(7):847–55. doi:10.1111/1759-7714.12759.
   PubMed Web of Science ®Google Scholar
• Danlos FX, Voisin AL, Dyevre V, Michot J-M, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21–29. doi:10.1016/j.ejca.2017.12.008.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, et al. Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur J Cancer. 2019;121:144–53. doi:10.1016/j.ejca.2019.08.014.
   PubMed Web of Science ®Google Scholar
• van der Kooij MK, Suijkerbuijk K, Aarts M, van den Berkmortel FW, Blank CU, Boers-Sonderen MJ, van Breeschoten J, van den Eertwegh AJ, de Groot JW, Haanen JB, et al. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease : a cohort study. Ann Intern Med. 2021;174(5):641–48. doi:10.7326/M20-3419.
   PubMed Web of Science ®Google Scholar
• Byeon S, Cho JH, Jung HA, Sun J-M, Lee S-H, Ahn JS, Park K, Ahn M-J. PD-1 inhibitors for non-small cell lung cancer patients with special issues: real-world evidence. Cancer Med. 2020;9(7):2352–62. doi:10.1002/cam4.2868.
   PubMed Web of Science ®Google Scholar
• Ansel S, Rulach R, Trotter N, Steele N. Pembrolizumab for advanced non-small cell lung cancer (NSCLC): impact of autoimmune comorbidity and outcomes following treatment completion. J Oncol Pharm Pract. 2022:10781552221079356. doi:10.1177/10781552221079356.
   Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. doi:10.1186/1745-6215-8-16.
   PubMed Web of Science ®Google Scholar
• Yang X, Karapetyan L, Kirkwood JM. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease. Ann Intern Med. 2021;174(9):1345. doi:10.7326/L21-0441.
   PubMed Web of Science ®Google Scholar
• Bottoni U, Paolino G, Ambrifi M, Didona D, Albanesi M, Clerico R, Lido P, Brachini A, Corsetti P, Richetta AG, et al. Association between autoimmune disease and cutaneous melanoma with regard to melanoma prognosis. Clin Exp Dermatol. 2015;40(3):254–59. doi:10.1111/ced.12531.
   PubMed Web of Science ®Google Scholar
• Faehling M, Schumann C, Christopoulos P, Didona D, Albanesi M, Clerico R, Lido P, Brachini A, Corsetti P, Richetta AG, et al. Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): real-world data on survival and safety from the German expanded-access program (EAP). Lung Cancer. 2020;150:114–22. doi:10.1016/j.lungcan.2020.10.006.
   PubMed Web of Science ®Google Scholar
• Gulati N, Celen A, Johannet P, Mehnert JM, Weber J, Krogsgaard M, Osman I, Zhong J. Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors. Cancer Med. 2021;10(21):7457–65. doi:10.1002/cam4.4239.
   PubMed Web of Science ®Google Scholar
• Han CY, Fitzgerald C, Lee M, Valero C, Gönen M, Shoushtari A, Morris LGT. Association between toxic effects and survival in patients with cancer and autoimmune disease treated with checkpoint inhibitor immunotherapy. JAMA Oncol. 2022;8(9):1352. doi:10.1001/jamaoncol.2022.2081.
   PubMed Web of Science ®Google Scholar
• Simonaggio A, Michot JM, Voisin AL, Le Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A, Varga A, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol. 2019;5(9):1310–17. doi:10.1001/jamaoncol.2019.1022.
   PubMed Web of Science ®Google Scholar
• Tison A, Quéré G, Misery L, Funck‐brentano E, Danlos F-X, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: a nationwide, multicenter cohort study. Arthritis Rheumatol. 2019;71(12):2100–11. doi:10.1002/art.41068.
   PubMed Web of Science ®Google Scholar
• Fountzilas E, Lampaki S, Koliou GA, Koumarianou A, Levva S, Vagionas A, Christopoulou A, Laloysis A, Psyrri A, Binas I, et al. Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. Cancer Immunol Immunother. 2022;71(2):327–37. doi:10.1007/s00262-021-02985-6.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Signorelli D, Ghidini M, Ghidini A, Pizzutilo EG, Ruggieri L, Cabiddu M, Borgonovo K, Dognini G, Brighenti M, et al. Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Cancers (Basel). 2020;12(3). doi:10.3390/cancers12030546.
   Web of Science ®Google Scholar
• Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: aSCO guideline update. J Clin Oncol. 2021;39(36):4073–126. doi:10.1200/JCO.21.01440.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2018;36:1714–68. doi:10.1200/JCO.2017.77.6385.
   PubMed Web of Science ®Google Scholar
• Naing A, Hajjar J, Gulley JL, Atkins MB, Ciliberto G, Meric-Bernstam F, Hwu P. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020;8(2):e001754. doi:10.1136/jitc-2020-001754.
   PubMed Web of Science ®Google Scholar
• Wagner G, Stollenwerk HK, Klerings I, Pecherstorfer M, Gartlehner G, Singer J. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review. Oncoimmunology. 2020;9(1):1774314. doi:10.1080/2162402X.2020.1774314.
   PubMed Web of Science ®Google Scholar
• Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res. 2016;22(4):886–94. doi:10.1158/1078-0432.CCR-15-1136.
   PubMed Web of Science ®Google Scholar
• Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, et al. Association of immune-related adverse events with nivolumab efficacy in non–small-cell lung cancer. JAMA Oncol. 2018;4(3):374–78. doi:10.1001/jamaoncol.2017.2925.
   PubMed Web of Science ®Google Scholar
• Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, Park SY, Yoon HI, Hong MH, Cho BC, et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol. 2019;145(6):1613–23. doi:10.1007/s00432-019-02899-y.
   PubMed Web of Science ®Google Scholar
• Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, et al. Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non–small-cell lung cancer. Clin Lung Cancer. 2019;20(3):201–07. doi:10.1016/j.cllc.2018.10.002.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, McQuade JL, Shoushtari AN, Tsai KK, Eroglu Z, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368–76. doi:10.1093/annonc/mdw443.
   PubMed Web of Science ®Google Scholar
• Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18(1):87. doi:10.1186/s12916-020-01549-2.
   PubMed Web of Science ®Google Scholar
• Guo J, Gao Y, Wang Y, Zou Y, Du Y, Luo C, Shi Y, Yang Y, Wu X, Su Y, et al. Investigation of C1-complex regions reveals new C1Q variants associated with protection from systemic lupus erythematosus, and affect its transcript abundance. Sci Rep. 2018;8(1):8048. doi:10.1038/s41598-018-26380-x.
   PubMedGoogle Scholar